Epidemiology Study of Malaria Transmission Intensity in Africa
NCT ID: NCT01190202
Last Updated: 2020-08-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21618 participants
INTERVENTIONAL
2011-03-14
2013-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia
NCT04241705
Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia
NCT06516042
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
NCT02974348
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso
NCT04695197
Antimalarial Drug Resistance in Mali
NCT00127998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There will be no study vaccine administered in this epidemiology study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Overall Study Group (Survey 1)
Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
Blood sampling
Capillary blood samples collected by finger/heel prick
Assessment of body temperature
Assessment of axial body temperature with a digital thermometer
Overall Study Group (Survey 2)
Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
Blood sampling
Capillary blood samples collected by finger/heel prick
Assessment of body temperature
Assessment of axial body temperature with a digital thermometer
Overall Study Group (Survey 3)
Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
Blood sampling
Capillary blood samples collected by finger/heel prick
Assessment of body temperature
Assessment of axial body temperature with a digital thermometer
Overall Study Group (Survey 4)
Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
Blood sampling
Capillary blood samples collected by finger/heel prick
Assessment of body temperature
Assessment of axial body temperature with a digital thermometer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Capillary blood samples collected by finger/heel prick
Assessment of body temperature
Assessment of axial body temperature with a digital thermometer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A male or female 6 months or older at the time of survey.
* Written informed consent obtained from the subject/from the parent(s)/ Legally Acceptable Representative(s) of the subject.
Exclusion Criteria
* Previous or current participation in any malaria vaccine trial.
6 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The PATH Malaria Vaccine Initiative (MVI)
OTHER
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Ouagadougou, , Burkina Faso
GSK Investigational Site
Lambaréné, , Gabon
GSK Investigational Site
Kintampo, , Ghana
GSK Investigational Site
Kumasi, , Ghana
GSK Investigational Site
Kisumu, , Kenya
GSK Investigational Site
Lilongwe, , Malawi
GSK Investigational Site
Dar es Salaam, , Tanzania
GSK Investigational Site
Korogwe, Tanga, , Tanzania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Drakeley C, Abdulla S, Agnandji ST, Fernandes JF, Kremsner P, Lell B, Mewono L, Bache BE, Mihayo MG, Juma O, Tanner M, Tahita MC, Tinto H, Diallo S, Lompo P, D'Alessandro U, Ogutu B, Otieno L, Otieno S, Otieno W, Oyieko J, Asante KP, Dery DB, Adjei G, Adeniji E, Atibilla D, Owusu-Agyei S, Greenwood B, Gesase S, Lusingu J, Mahende C, Mongi R, Segeja M, Adjei S, Agbenyega T, Agyekum A, Ansong D, Bawa JT, Boateng HO, Dandalo L, Escamilla V, Hoffman I, Maenje P, Martinson F, Carter T, Leboulleux D, Kaslow DC, Usuf E, Pircon JY, Bahmanyar ER. Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries. Malar J. 2017 Oct 27;16(1):433. doi: 10.1186/s12936-017-2078-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
114001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.